Pharmacogenetics of disease-modifying anti-rheumatic drugs

Best Practice and Research: Clinical Rheumatology

Volumn 18, Issue 2, 2004, Pages 233-247

  Tanaka, E ^a   Taniguchi, A ^a   Urano, W ^a   Yamanaka, H ^a   Kamatani, N ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse effect; Diplotype configuration; N acetyltransferase 2; Polymorphism; Rheumatoid arthritis (RA); Sulphasalazine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIRHEUMATIC AGENT; ARYLAMINE ACETYLTRANSFERASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FOLIC ACID; FOLINIC ACID; GLUTATHIONE TRANSFERASE; HYDRALAZINE; HYDROXYCHLOROQUINE; ISONIAZID; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; N DESETHYLHYDROXYCHLOROQUINE; PENICILLAMINE; PROCAINAMIDE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; DIPLOPIA; DNA POLYMORPHISM; DRUG ACETYLATION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; DRUG URINE LEVEL; GASTROINTESTINAL SYMPTOM; GENETIC CORRELATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 2542486410     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.02.006     Document Type: Review

References (61)

1. Furst DE & Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis and Rheumatism 1988; 31: 305-314.
2. Felson DT, Anderson JJ & Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis and Rheumatism 1990; 33: 1449-1461.
3. van Ede AE, Laan RF, Blom HJ, et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Seminars in Arthritis and Rheumatism 1998; 27: 277-292.
4. Ranganathan P, Eisen S, Yokoyama WM & McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Annals of the Rheumatic Diseases 2003; 62: 4-9.
5. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-113.
6. Bagley PJ & Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 13217-13220.
7. Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molecular Genetics and Metabolism 1998; 64: 169-172.
8. Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1999; 58: 79-84.
9. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis and Rheumatism 2001; 44: 2525-2530.
10. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 183-190.
11. Kitamura Y, Moriguchi M, Kaneko H, et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Annals of Human Genetics 2002; 66: 183-193.
12. Kumagai K, Hiyama K, Oyama T, et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. International Journal of Molecular Medicine 2003; 11: 593-600.
13. Mitomo H, Kato R, Ito A, et al. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochemical Journal 2003; 373: 767-774.
14. Rains CP, Noble S & Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995; 50: 137-156.
15. Timbrell JA, Wright JM & Baillie TA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clinical Pharmacology and Therapeutics 1977; 22: 602-609.
16. Pullar T, Hunter JA & Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Annals of the Rheumatic Diseases 1985; 44: 831-837.
17. Kitas GD, Farr M, Waterhouse L & Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 1992; 21: 220-225.
18. Chalmers IM, Sitar DS & Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. Journal of Rheumatology 1990; 17: 764-770.
19. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of the USA 1991; 88: 5237-5241.
20. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14: 1689-1692.
21. Deguchi T, Mashimo M & Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. Journal of Biological Chemistry 1990; 265: 12757-12760.
22. Hickman D & Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochemical Pharmacology 1991; 42: 1007-1014.
23. Lin HJ, Han CY, Lin BK & Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-134.
24. Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. Journal of Rheumatology 2002; 29: 2492-2499.
25. Laversuch CJ, Collins DA, Charles PJ & Bourke BE. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. British Journal of Rheumatology 1995; 34: 435-439.
26. Gunnarsson I, Kanerud L, Pettersson E, et al. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. British Journal of Rheumatology 1997; 36: 1089-1094.
27. Sabbagh N, Delaporte E, Marez D, et al. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997; 7: 131-135.
28. Ohtani T, Hiroi A, Sakurane M & Furukawa F. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. British Journal of Dermatology 2003; 148: 1035-1039.
29. Wadelius M, Stjernberg E, Wiholm BE & Rane A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 2000; 10: 35-41.
30. Munro R & Capell HA. Disease-modifying drugs series. Penicillamine. British Journal of Rheumatology 1997; 36: 104- 109.
31. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutation Research 2000; 463: 247-283.
32. Layton MA, Jones PW, Alldersea JE, et al. The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. Rheumotology (Oxford) 1999; 38: 43-47.
33. Mattey DL, Hutchinson D, Dawes PT, et al. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase MI locus. Arthritis and Rheumatism 2002; 46: 640-646.
34. Mattey DL, Hassell AB, Plant M, et al. Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Annals of the Rheumatic Diseases 1999; 58: 164-168.
35. McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clinical Pharmacology and Therapeutics 1994; 55: 15-20.
36. Weinshilboum RM & Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics 1980; 32: 651-662.
37. McLeod HL & Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
38. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Annals of Internal Medicine 1997; 126: 608-614.
39. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. Journal of the National Cancer Institute 1999; 91: 2001-2008.
40. Ensom MH, Chang TK & Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clinical Pharmacokinetics 2001; 40: 783-802.
41. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Annals of Internal Medicine 1998; 129: 716-718.
42. Ishioka S, Hiyama K, Sato H, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Internal Medicine 1999; 38: 944-947.
43. Corominas H, Domenech M, Laiz A, et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology (Oxford) 2003; 42: 40-45.
44. Marra CA, Esdaile JM & Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. Journal of Rheumatology 2002; 29: 2507-2512.
45. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F, et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999; 9: 189-198.
46. Yan L, Zhang S, Eiff B, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clinical Pharmacology and Therapeutics 2000; 68: 210-219.
47. Chang TK, Weber GF, Crespi CL & Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research 1993; 53: 5629-5637.
48. Chang TK, Yu L, Goldstein JA & Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7: 211-221.
49. Bohnenstengel F, Hofmann U, Eichelbaum M & Kroemer HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. European Journal of Clinical Pharmacology 1996; 51: 297-301.
50. Cush JJ, Tugwell P, Weinblatt M & Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. Journal of Rheumatology 1999; 26: 1176-1186.
51. Min DI & Ellingrod VL. Association of the CYP3A4* IB 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Therapeutic Drug Monitoring 2003; 25: 305-309.
52. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-I C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clinical Chemistry 2001; 47: 1048-1052.
53. Rivory LP, Qin H, Clarke SJ, et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. European Journal of Clinical Pharmacology 2000; 56: 395-398.
54. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDRI polymorphic expression on cyclosporine oral disposition in renal transplant patients. The Journal of Clinical Pharmacology 2003; 43: 555-564.
55. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDRI and CYP3A4 genes in Asians and the influence of MDRI haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89-95.
56. Rozman B. Clinical pharmacokinetics of leflunomide. Clinical Pharmacokinetics 2002; 41: 421-430.
57. Kalgutkar AS, Nguyen HT, Vaz AD, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome p450-catalyzed dehydration of aldoximes. Drug Metabolism and Disposition 2003; 31: 1240-1250.
58. Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metabolism and Disposition 2003; 31: 748-754.
59. Kim KA, Park JY, Lee JS & Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Archives of Pharmacal Research 2003; 26: 631-637.
60. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis and Rheumatism 2002; 46: 1460-1469.
61. Shroyer NF, Lewis RA & Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? American Journal of Ophthalmology 2001; 131: 761-766.